Technical Analysis for PRAX - Praxis Precision Medicines, Inc.

Grade Last Price % Change Price Change
C 54.57 -1.03% -0.57
PRAX closed down 1.03 percent on Monday, March 18, 2024, on 74 percent of normal volume.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down

Date Alert Name Type % Chg
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Pocket Pivot Bullish Swing Setup -1.03%
Outside Day Range Expansion -1.03%
Wide Bands Range Expansion -1.03%
MACD Bearish Signal Line Cross Bearish 2.96%
Wide Bands Range Expansion 2.96%

   Recent Intraday Alerts

Alert Time
Possible Inside Day about 13 hours ago
60 Minute Opening Range Breakdown about 14 hours ago
Down 1% about 14 hours ago
Fell Below 10 DMA about 15 hours ago
Reversed from Up about 15 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Praxis Precision Medicines, Inc. Description

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement Purdue Neuroscience Company; and a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc. The company was incorporated in 2015 and is based in Cambridge, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Neuroscience Central Nervous System Disorders Precision Medicine Epilepsy Major Depressive Disorder Nervous System Disorders Depression Depressive Disorder Huntington's Disease Oligonucleotide Treatment Of Major Depressive Disorder Spinal Muscular Atrophy Neuron Antisense RNA Essential Tremor Receptor Positive Ionis Perimenopausal Depression

Is PRAX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 59.975
52 Week Low 11.85
Average Volume 169,696
200-Day Moving Average 24.71
50-Day Moving Average 44.32
20-Day Moving Average 50.37
10-Day Moving Average 54.97
Average True Range 3.57
RSI (14) 61.54
ADX 44.85
+DI 30.04
-DI 14.15
Chandelier Exit (Long, 3 ATRs) 49.28
Chandelier Exit (Short, 3 ATRs) 49.45
Upper Bollinger Bands 61.89
Lower Bollinger Band 38.86
Percent B (%b) 0.68
BandWidth 45.72
MACD Line 3.70
MACD Signal Line 3.89
MACD Histogram -0.1948
Fundamentals Value
Market Cap 711.44 Million
Num Shares 13 Million
EPS -29.55
Price-to-Earnings (P/E) Ratio -1.85
Price-to-Sales 298.20
Price-to-Book 6.77
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 57.56
Resistance 3 (R3) 57.81 57.07 57.06
Resistance 2 (R2) 57.07 56.31 56.94 56.89
Resistance 1 (R1) 55.82 55.84 55.45 55.57 56.73
Pivot Point 55.08 55.08 54.90 54.95 55.08
Support 1 (S1) 53.83 54.32 53.46 53.58 52.41
Support 2 (S2) 53.09 53.85 52.96 52.25
Support 3 (S3) 51.84 53.09 52.08
Support 4 (S4) 51.59